[go: up one dir, main page]

WO2005056598A3 - Laminin-5 modulators and uses thereof - Google Patents

Laminin-5 modulators and uses thereof Download PDF

Info

Publication number
WO2005056598A3
WO2005056598A3 PCT/DK2004/000860 DK2004000860W WO2005056598A3 WO 2005056598 A3 WO2005056598 A3 WO 2005056598A3 DK 2004000860 W DK2004000860 W DK 2004000860W WO 2005056598 A3 WO2005056598 A3 WO 2005056598A3
Authority
WO
WIPO (PCT)
Prior art keywords
laminin
modulators
disorders
disease
exemplary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2004/000860
Other languages
French (fr)
Other versions
WO2005056598A2 (en
Inventor
Ida Stenfeldt Mathiasen
Michael Karl Bauer
Joern Roland Mueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to EP04803013A priority Critical patent/EP1694839A2/en
Priority to JP2006543368A priority patent/JP2008502588A/en
Publication of WO2005056598A2 publication Critical patent/WO2005056598A2/en
Publication of WO2005056598A3 publication Critical patent/WO2005056598A3/en
Priority to US11/451,583 priority patent/US20070014788A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Described herein are methods of treating or preventing various diseases and disorders using modulators of laminin-5. Exemplary diseases and disorders are inflammatory bowel disease, including ulcerative colitis and Crohn's disease, as well as polycystic kidney disease and cancers associated with one or more of the aforementioned conditions. Exemplary laminin-5 modulators include monoclonal antibodies against the laminin-5 gamma2 chain and short interfering RNA (siRNA) sequences against nucleotide sequences encoding the laminin-5 gamma2 chain. Described are also combination treatments based on the administration of a laminin-5 modulator and at least one other therapeutic agent.
PCT/DK2004/000860 2003-12-12 2004-12-13 Laminin-5 modulators and uses thereof Ceased WO2005056598A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04803013A EP1694839A2 (en) 2003-12-12 2004-12-13 Laminin-5 modulators and uses thereof
JP2006543368A JP2008502588A (en) 2003-12-12 2004-12-13 Laminin-5 modulator and use thereof
US11/451,583 US20070014788A1 (en) 2004-12-13 2006-06-12 Laminin-5 modulators and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52906703P 2003-12-12 2003-12-12
US60/529,067 2003-12-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/451,583 Continuation US20070014788A1 (en) 2004-12-13 2006-06-12 Laminin-5 modulators and uses thereof

Publications (2)

Publication Number Publication Date
WO2005056598A2 WO2005056598A2 (en) 2005-06-23
WO2005056598A3 true WO2005056598A3 (en) 2005-11-03

Family

ID=34676870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000860 Ceased WO2005056598A2 (en) 2003-12-12 2004-12-13 Laminin-5 modulators and uses thereof

Country Status (3)

Country Link
EP (1) EP1694839A2 (en)
JP (1) JP2008502588A (en)
WO (1) WO2005056598A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8545845B2 (en) 2008-06-18 2013-10-01 Karl Tryggvason Antibodies against domains of laminin-332

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2198884A1 (en) 2008-12-18 2010-06-23 Centre National de la Recherche Scientifique (CNRS) Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5
KR102001582B1 (en) 2011-08-08 2019-07-18 큐어랩 온콜로지, 인크. Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
CN103149371B (en) * 2013-02-26 2015-12-23 哈药慈航制药股份有限公司 The application of biomarker in the feedback response medicine of preparation prediction 5-aminosalicylic acid treatment ulcerative colitis
TWI676681B (en) * 2017-03-29 2019-11-11 臺北醫學大學 Antigen-specific T cells and uses thereof
CN110646624B (en) * 2019-10-31 2023-07-07 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） A kind of ELISA reagent diagnostic kit of stromalin 2 and its application method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010646A1 (en) * 1994-10-04 1996-04-11 Karl Tryggvason Laminin chains: diagnostic and therapeutic use
WO2000026342A1 (en) * 1998-10-30 2000-05-11 Northwestern University Method of interfering with cell proliferation
WO2002030465A2 (en) * 2000-10-12 2002-04-18 University Of Rochester Compositions that inhibit proliferation of cancer cells
WO2003099298A1 (en) * 2002-05-24 2003-12-04 Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010646A1 (en) * 1994-10-04 1996-04-11 Karl Tryggvason Laminin chains: diagnostic and therapeutic use
WO2000026342A1 (en) * 1998-10-30 2000-05-11 Northwestern University Method of interfering with cell proliferation
WO2002030465A2 (en) * 2000-10-12 2002-04-18 University Of Rochester Compositions that inhibit proliferation of cancer cells
WO2003099298A1 (en) * 2002-05-24 2003-12-04 Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOUATROUSS YAMINA ET AL: "Altered expression of laminins in Crohn's disease small intestinal mucosa", AMERICAN JOURNAL OF PATHOLOGY, vol. 156, no. 1, January 2000 (2000-01-01), pages 45 - 50, XP002333418, ISSN: 0002-9440 *
HABERMANN J ET AL: "Ulcerative colitis and colorectal carcinoma: DNA-profile, laminin-5 gamma2 chain and cyclin A expression as early markers for risk assessment", SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 36, no. 7, July 2001 (2001-07-01), pages 751 - 758, XP008048927, ISSN: 0036-5521 *
MASAKI TADAHIKO ET AL: "Coexpression of matrilysin and laminin-5 gamma2 chain may contribute to tumor cell migration in colorectal carcinomas.", DIGESTIVE DISEASES AND SCIENCES, vol. 48, no. 7, July 2003 (2003-07-01), pages 1262 - 1267, XP008048872, ISSN: 0163-2116 *
PIRILA EMMA ET AL: "Gelatinase A (MMP-2), collagenase-2 (MMP-8), and laminin-5 gamma2-chain expression in murine inflammatory bowel disease (ulcerative colitis).", DIGESTIVE DISEASES AND SCIENCES, vol. 48, no. 1, January 2003 (2003-01-01), pages 93 - 98, XP008048871, ISSN: 0163-2116 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8545845B2 (en) 2008-06-18 2013-10-01 Karl Tryggvason Antibodies against domains of laminin-332

Also Published As

Publication number Publication date
WO2005056598A2 (en) 2005-06-23
EP1694839A2 (en) 2006-08-30
JP2008502588A (en) 2008-01-31

Similar Documents

Publication Publication Date Title
WO2003031475A3 (en) Antibodies against kdr, their production and uses
WO2004096016A3 (en) Modulation of glucagon receptor expression
WO2001082899A3 (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
WO2006064453A3 (en) Targeting agents for molecular imaging
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2002020762A3 (en) Tnf receptor-like molecules and uses thereof
WO2007034188A3 (en) Chemo-immunotherapy method
WO2004048534A3 (en) Modulation of cytokine-inducible kinase expression
WO2006002437A3 (en) Treatment of conditions involving demyelination
WO2004096996A3 (en) Modulation of glucagon receptor expression
WO2001072822A3 (en) Genes involved in intestinal inflammatory diseases and use thereof
TW200507840A (en) Method of treating multiple myeloma
WO2002081745A3 (en) Genes involved in osteogenesis, and methods of use
WO2005056598A3 (en) Laminin-5 modulators and uses thereof
WO2005042552A3 (en) Modulation of sglt2 expression
WO2002010388A3 (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2003055980A3 (en) Il-17 like molecules and uses thereof
WO2004047741A3 (en) Modulation of iap-like expression
WO2005006958A3 (en) Modulation of ceacam1 expression
WO2004047750A3 (en) Modulation of notch2 expression
WO2004047731A3 (en) Modulation of notch3 expression
WO2004048601A3 (en) Modulation of b7h expression
WO2004043398A3 (en) Modulation of jumonji expression
WO2004048524A3 (en) Modulation of stat2 expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004803013

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006543368

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11451583

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004803013

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11451583

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2004803013

Country of ref document: EP